|

Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy

RECRUITINGPhase 3Sponsored by Tanta University
Actively Recruiting
PhasePhase 3
SponsorTanta University
Started2018-11-01
Est. completion2028-11
Eligibility
Age20 Years – 65 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04161053

Summary

Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.

Eligibility

Age: 20 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Cirrhotic patient with at least one previous episode of hepatic encephalopathy.
* Adult Patients aging from 20 to 65 years old

Exclusion Criteria:

* Active GIT bleeding.
* Major psychiatric illness (psychosis \& epilepsy).
* Renal insufficiency (S.Cr 2mg/dl).

Conditions2

Hepatic EncephalopathyLiver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.